Shanghai GenTech Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Shanghai GenTech heeft een totaal eigen vermogen van CN¥3.5B en een totale schuld van CN¥1.3B, wat de schuld-eigenvermogensverhouding op 36.7% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥9.3B en CN¥5.8B. De EBIT Shanghai GenTech is CN¥480.8M waardoor de rentedekking 35.3 is. Het heeft contanten en kortetermijnbeleggingen van CN¥1.1B.

Belangrijke informatie

36.7%

Verhouding schuld/eigen vermogen

CN¥1.28b

Schuld

Rente dekkingsratio	35.3x
Contant	CN¥1.10b
Aandelen	CN¥3.49b
Totaal verplichtingen	CN¥5.82b
Totaal activa	CN¥9.31b

Recente financiële gezondheidsupdates

Does Shanghai GenTech (SHSE:688596) Have A Healthy Balance Sheet?

Jul 29

Recent updates

Shanghai GenTech's (SHSE:688596) Profits May Not Reveal Underlying Issues

Nov 06

Shanghai GenTech Co., Ltd. (SHSE:688596) Stock Rockets 28% But Many Are Still Ignoring The Company

Oct 01

A Piece Of The Puzzle Missing From Shanghai GenTech Co., Ltd.'s (SHSE:688596) 26% Share Price Climb

Mar 03

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥7.2B ) 688596 } overtreffen de korte termijn passiva ( CN¥5.2B ).

Langlopende schulden: De kortetermijnactiva 688596 ( CN¥7.2B ) overtreffen de langetermijnschulden ( CN¥577.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 5.1% ) 688596 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 688596 is de afgelopen 5 jaar gestegen van 27.1% naar 36.7%.

Schuldendekking: De operationele kasstroom van 688596 is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: De rentebetalingen op de schuld van 688596 worden goed gedekt door EBIT ( 35.3 x dekking).

Shanghai GenTech Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Shanghai GenTech (SHSE:688596) Have A Healthy Balance Sheet?

Recent updates

Shanghai GenTech's (SHSE:688596) Profits May Not Reveal Underlying Issues

Third quarter 2024 earnings released: EPS: CN¥0.80 (vs CN¥0.45 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

Shanghai GenTech Co., Ltd. (SHSE:688596) Stock Rockets 28% But Many Are Still Ignoring The Company

Shanghai GenTech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 19%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.53 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Does Shanghai GenTech (SHSE:688596) Have A Healthy Balance Sheet?

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 50 million worth of its shares.

Shanghai GenTech Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sentiment Still Eluding Shanghai GenTech Co., Ltd. (SHSE:688596)

Price target decreased by 9.8% to CN¥46.00

Do Shanghai GenTech's (SHSE:688596) Earnings Warrant Your Attention?

New minor risk - Dividend sustainability

Shanghai GenTech's (SHSE:688596) Profits May Not Reveal Underlying Issues

First quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.04 in 1Q 2023)

Shanghai GenTech Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Shanghai GenTech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Returns On Capital At Shanghai GenTech (SHSE:688596) Have Stalled

A Piece Of The Puzzle Missing From Shanghai GenTech Co., Ltd.'s (SHSE:688596) 26% Share Price Climb

Full year 2023 earnings: EPS exceeds analyst expectations

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 50 million worth of its shares.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Third quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.33 in 3Q 2022)

Price target decreased by 9.4% to CN¥52.00

Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.19 in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 1Q 2022)

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 12% to CN¥50.50

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.21 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanghai GenTech Co., Ltd. announced that it expects to receive CNY 300 million in funding

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 120 million worth of its shares.

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.17 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.07 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.48 (vs CN¥0.45 in FY 2019)

New 90-day low: CN¥15.90

Investor sentiment deteriorated over the past week

New 90-day low: CN¥18.86

New 90-day low: CN¥20.75

Shanghai GenTech Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven